220 E FIRST ST, BETHLEHEM, PA
Investor Presentation
Director Resignation - David J. Shulkin Steps Down from Board
Announces Fourth Quarter 2025 Financial Results
Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
Other Events
Announces Third Quarter 2025 Financial Results
Resignation of Mara G. Aspinall; John P. Kenny Appointed Chair
Announces Second Quarter 2025 Financial Results
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Additional Information Statement
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload